anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread musculoskeletal pain and various associated symptoms. Non-pharmacological interventions have gained attention for managing FMS and improving patient outcomes. We reviewed past research to investigate the effects of traditional Chinese martial arts (TCMA) and stretching training (ST) on symptoms of patients with FMS. We searched Web of Science, Medline via PubMed, the Cochrane Library, and EMBASE from their inceptions to June 1, 2023. Across selected studies, we evaluated TCMA and ST using Fibromyalgia Impact Questionnaire (FIQ) scores, pain symptoms, fatigue levels, and sleep quality as outcome measures. Compared with control groups, participants receiving TCMA and ST interventions showed significantly lower FIQ scores (Standard Mean Difference (SMD) = -3.01, 95% Confidence Interval (CI) [-4.83,-1.19]), improved pain symptoms (SMD = -0.77, 95% CI [-1.07,-0.47]), less fatigue (SMD = 1.31, 95% CI [0.50,2.11]), and enhanced sleep quality (SMD = -0.55, 95% CI [-0.97,-0.12]). Subgroup analyses revealed that, irrespective of intervention duration, both TCMA and ST interventions were effective in relieving pain symptoms in these patients. ST interventions showed significant improvement in fatigue symptoms, while TCMA interventions positively influenced sleep quality. These findings highlight potential non-pharmalogical benefits of TCMA and ST interventions in managing FMS. However, future research should explore the optimal duration, frequency, intensity, and types of interventions for TCMA and ST and design targeted exercise intervention programs to study the effects of these interventions on different characteristics of FMS patients. Attention should be given to the effects of short-term interventions on improving fatigue symptoms, sleep quality, and pain relief, to provide more personalized and effective FMS treatment plans.
SCOPE: Diets rich in fat and sugars evoke chronic low-grade inflammation, leading to metabolic derangements. This study investigates the impact of fructose and galactose, two commonly consumed simple sugars, on exacerbation of the harmful effects caused by high fat intake. Additionally, the potential efficacy of fructooligosaccharides (FOS), a fermentable dietary fiber, in counteracting these effects is examined.
METHODS AND RESULTS: Male Sprague-Dawley rats (six/group) are fed 8 weeks as follows: control 5% fat diet (CNT), 20% fat diet (FAT), FAT+10% FOS diet (FAT+FOS), FAT+25% galactose diet (FAT+GAL), FAT+GAL+10% FOS diet (FAT+GAL+FOS), FAT+25% fructose diet (FAT+FRU), FAT+FRU+10% FOS diet (FAT+FRU+FOS). The dietary manipulations tested do not affect body weight gain, blood glucose, or markers of systemic inflammation whereas significant increases in plasma concentrations of triacylglycerols, cholesterol, aspartate aminotransferase, and alanine aminotrasferase are detected in both FAT+FRU and FAT+GAL compared to CNT. In the liver and skeletal muscle, both sugars induce significant accumulation of lipids and advanced glycation end-products (AGEs). FOS supplementation prevents these impairments.
CONCLUSION: This study extends the understanding of the deleterious effects of a chronic intake of simple sugars and demonstrates the beneficial role of the prebiotic FOS in dampening the sugar-induced metabolic impairments by prevention of lipid and AGEs accumulation.
Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
Exemplary embodiments provide computer-implemented methods, mediums, and apparatuses configured to provide an interactive analytical method debugger for an analytical laboratory system. The analytical laboratory system may include a laboratory analytical device with a number of settings, parameters, etc. The laboratory analytical device may process a sample according to an analytical method that (among other things) defines a configuration for the device. The settings for the method may be organized into categories. The interactive debugger identifies problems with the method (e.g., incompatibilities, values out of range, etc.) and automatically allow the user to view the category of the method that is relevant to addressing the issue. Possible solutions may be proposed in the debugger interface, allowing the user to quickly identify and address the problem. Embodiments are particularly well-suited to situations where a method is ported from an old device to a new device.
Exosomes derived from mesenchymal stem cells have shown promise in treating metabolic disorders, yet their specific mechanisms remain largely unclear. This study investigates the protective effects of exosomes from human umbilical cord Wharton's jelly mesenchymal stem cells (hWJMSCs) against adiposity and insulin resistance in high-fat diet (HFD)-induced obese mice. HFD-fed mice treated with hWJMSC-derived exosomes demonstrated improved gut barrier integrity, which restored immune balance in the liver and adipose tissues by reducing macrophage infiltration and pro-inflammatory cytokine expression. Furthermore, these exosomes normalized lipid metabolism including lipid oxidation and lipogenesis, which alleviate lipotoxicity-induced endoplasmic reticulum (ER) stress, thereby decreasing fat accumulation and chronic tissue inflammation in hepatic and adipose tissues. Notably, hWJMSC-derived exosomes also promoted browning and thermogenic capacity of adipose tissues, which was linked to reduced fibroblast growth factor 21 (FGF21) resistance and increased adiponectin production. This process activated the AMPK-SIRT1-PGC-1α pathway, highlighting the role of the FGF21-adiponectin axis. Our findings elucidate the molecular mechanisms through which hWJMSC-derived exosomes counteract HFD-induced metabolic dysfunctions, supporting their potential as therapeutic agents for metabolic disorders.
Spore-forming bacteria have a unique resistance to negative environmental conditions, including aggressive space factors, and are an excellent model for studying adaptation mechanisms and survival strategies at the molecular level. The study analyzed the genome of Bacillus velezensis, which remained viable after a 2-year exposure in outer space on the outer surface of the ISS as part of the Test space experiment. A comparative analysis of the draft genomes of the exhibit strain and the ground control did not reveal significant changes; the average nucleotide identity was 99.98%, which indicates the ability of microorganisms to maintain genome stability in space conditions, due to both increased stress resistance of bacterial spores and efficient operation of the system of repair of accumulated changes. The study of a single nucleotide polymorphism in the genome of B. velezensis revealed nine point substitutions, three of which are in intergenic regions, six in protein-coding genes, three of them are missense mutations, two nucleotide deletions leading to a shift in the reading frame, and one synonymous substitution. The profiles of the housekeeping genes were determined during MLST typing and it was found that the allelic profiles obtained for B. velezensis T15.2 and 924 strains do not correspond to any of the previously described sequence types. The presented results indicate the ability of B. velezensis bacteria to maintain the viability of spores and the integrity of the genome for a long time under extreme conditions of outer space, which is important for the problem of planetary protection, as well as the potential possibility of performing biotechnological processes based on B. velezensis during space exploration.
Participants (\> 1 month and \< 3 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
Persistent pressure overload commonly leads to pathological cardiac hypertrophy and remodeling, ultimately leading to heart failure (HF). Cardiac remodeling is associated with the involvement of immune cells and the inflammatory response in pathogenesis. The macrophage-1 antigen (Mac-1) is specifically expressed on leukocytes and regulates their migration and polarization. Nonetheless, the involvement of Mac-1 in cardiac remodeling and HF caused by pressure overload has not been determined. The Mac-1-knockout (KO) and wild-type (WT) mice were subjected to transverse aortic constriction (TAC) for 6 weeks. Echocardiography and pressure-volume loop assessments were used to evaluate cardiac function, and cardiac remodeling and macrophage infiltration and polarization were estimated by histopathology and molecular techniques. The findings of our study demonstrated that Mac-1 expression was markedly increased in hearts subjected to TAC treatment. Moreover, compared with WT mice, Mac-1-KO mice exhibited dramatically ameliorated TAC-induced cardiac dysfunction, hypertrophy, fibrosis, oxidative stress and apoptosis. The potential positive impacts may be linked to the inhibition of macrophage infiltration and M1 polarization via reductions in NF-kB and STAT1 expression and upregulation of STAT6. In conclusion, this research reveals a new function of Mac-1 deficiency in reducing pathological cardiac remodeling and HF caused by pressure overload. Additionally, inhibiting Mac-1 could be a potential treatment option for patients with HF in a clinical setting.
NEW MATERIAL:A compound shown by formula I (R1 an R2 are lower alkyl; R3 and R4 are H, halogen, lower alkyl, lower alkoxy or CF3) and an acid addi tion salt thereof. EXAMPLE:N-[4,5-Dimethoxy-2-( 4-methylphenyl )aminocarbonylphenyl]-4-methyl- piperazineacetamide.hydrocyloride. USE:A drug. A remedy for urination disorder such as pollakisuria, feeling of residual urine, etc. A dose is 10-1,000mg calculated as active ingredient/adult/day. PREPARATION:A compound shown by formula IV is reduced with a reducing agent to give a compound shown by formula V, which is reacted with a com pound shown by formula VI (X is halogen) to give a halogenoacetamide deriva tive shown by formula II of novel compound, which is reacted with an N- alkylpiperazine shown by formula III in a solvent such as N,N- dimethylformamide, etc., at room temperature - under reflux of the solvent under heating to give a compound shown by formula I.
Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
A raster scan cathode ray tube (CRT) display system which is capable of indirectly addressing data to be displayed in an manner presenting the data on any selected row or group of rows, in any order. A scrolling system according to the invention includes a cathode ray tube controller (CRTC) coupled to an indirect address counter which is coupled together with a presettable counter through a multiplexer (MUX) to the address port of a CRT display refresh memory (RAM), a segment of the data output port of the refresh memory being coupled to the preset port of the presettable counter. The invention operates by generating a refresh address indirectly through the presettable counter which addresses pointers in the refresh memory, each pointer containing the absolute address of the beginning of a specific line of data in the refresh memory which is to be displayed. During the blanking interval of the display, data is addressed by the indirect address counter. During other intervals, the address presented to the refresh memory is generated by the refresh address counter (the presettable binary counter). The address which is provided at the refresh address counter dictates the line of characters which are therafter displayed.
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology, specifically to a method of producing a product of Factor VIII, having an improved ratio of FVIII:C/FVIII:Ag, by chromatography, and to a product which is obtained using said method. Method of producing product Factor VIII, having ratio FVIII:C/FVIII:Ag of at least 0.7 in product Factor VIII, is carried out by chromatography, where at least one chromatographic step is carried out using an affinity chromatographic resin, on which 13 kDa immobilized Fab antibody fragment derived from yeast is directed against Factor VIII molecule. Binding Factor VIII with affinity resin is carried out in conditions of low concentration of salt, equivalent concentration of 0.1–0.5 mol/kg of sodium chloride. Washing of resin is carried out at high concentration of salt in range of 0.3–4 mol/kg of sodium chloride for light chain removal. Elution and collection of Factor VIII is carried out by using concentration of salt in range of 0.5–4 mol/kg of sodium chloride in combination with 40–60 % of ethylene glycol. Produced Factor VIII product contains more than 98 % of monomer and essentially does not have Aggregated Factor VIII, is suitable for treating haemophilia and eliminating formation of Factor VIII product inhibitors.EFFECT: said product is stable, preserves its biological activity, high content of monomer Factor VIII in the state of freezing and/or lyophilisation for at least 6 months.15 cl, 23 dwg, 14 tbl, 10 ex
Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
OBJECTIVE: CTD-related immune thrombocytopenia (CTD-ITP) represents an unmet medical need because the drugs that are available are only partly effective and have considerable side-effects. The aim of this study was to assess the efficacy and safety of sirolimus in refractory CTD-ITP patients.
METHODS: We did a single-arm, open-label, pilot study of sirolimus in patients with CTD-ITP unresponsive to, or intolerant of, conventional medications. Patients received oral sirolimus for 6 months at a starting dose of 0.5-1 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/ml. The primary efficacy end point was changes in platelet count, and overall response assessed according to the ITP International Working Group Criteria. Safety outcomes included tolerance as assessed by the occurrence of common side-effects.
RESULTS: Between November 2020 and February 2022, 12 consecutively hospitalized patients with refractory CTD-ITP were enrolled and prospectively followed. Of these, six patients (50%) achieved complete response, two (16.7%) achieved partial response, and four (33.3%) were no response under therapy. Three of four patients with primary Sjögren's syndrome and two of three patients with systemic lupus erythematosus achieved overall response. One of two patients with overlapping Sjögren's syndrome and systemic lupus erythematosus achieved complete response at 6 months. No severe drug-related toxicities were observed.
CONCLUSION: Our results do support sirolimus as an alternative regimen for refractory CTD-ITP patients, including systemic lupus erythematosus and primary SS.
Patients candidates to posterior spine surgery (Micro-discectomy, Lumbar laminectomy with or without fusion, cervical laminectomy) are asked to participate to this prospective study. After verification of inclusion and exclusion criteria, patients consenting to enter the study are randomly assigned to one of the following subgroups: 1-Pre-incisional wound infiltration with 20 mL of bupivacaine 0.25%. 2- Pre-incisional wound infiltration with 150 μg of clonidine with 20 mL of bupivacaine 0.25%. Demographic parameters, co-morbidities and other pre and per operative medical data are noted. In the post-operative period, patients received a standardized post-operative analgesic protocol (NSAI and paracetamol). Patients are asked to fill their pain diary using Visual Analog Scale (VAS) from day 0 till day 8 after surgery. Morphine rescue consumption is noted. Finally, the percentage of global subjective patient satisfaction regarding the post-operative wound pain is noted from 0 to 100.
396,055. Dentifrices. GULBRANSEN, S. G., Larvik, Norway. Jan. 22, 1932, No. 2007. Convention date, Jan. 23, 1931. [Class 131.] A tooth paste is prepared by evaporating the juice of fruit or berries to a syrup, filling such syrup into' tubes, and then cooling, the syrup being initially of such consistency that when cooled it thickens into a paste which is selfpreserving. The juice is normally evaporated to one-third to one-fifth of its volume, but in the case of juice having a low solid content or a low percentage of constituents having a preserving character, further evaporation may be necessary. Glycerine up to 5 per cent, or a thickening agent up to 20 per cent of the final product, may be added to the juice before evaporation. Suitable thickening agents are soapstone powder, asbestos powder, prepared chalk, or clay. In examples the paste is prepared from tomato juice containing 1 per cent of glycerine, and from the juice of red whortleberries mixed with 10 per cent of prepared chalk and 1 per cent of glycerine.
Participants will receive Treatment A (one spray of oromucosal nicotine spray \[ONS\]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette \[10 puffs\]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
Cross sensitivity and/or related problems \- patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers.

Pregnancy Category C - Hyoscyamine Sulfate and Methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether Utira™-C Tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Utira™-C Tablets should be given to a pregnant woman only if clearly needed. 

Breast-feeding - Problems in humans have not been documented, however, Methenamine and traces of Hyoscyamine Sulfate are excreted in breast milk. Accordingly, Utira™-C Tablets should be given to a nursing woman only if clearly needed. 

Prolonged Use - there have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.

Pediatric - Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.   
  
Geriatric - Use with caution in elderly patients as they may respond to usual doses of Hyoscyamine Sulfate with excitement, agitation, drowsiness, or confusion.
PURPOSE:To obtain a perfuming agent which suppress the volatilization of perfuming substances and emits a sweet smell for a long time by coating and impregnating an object with an alcoholic soln. of a vinyl acetate resin and a perfume and evaporating the alcohol. CONSTITUTION:A perfuming agent wherein a homogeneous mixture of a perfume and a vinyl acetate resin remains, obtd. by coating and impregnating an object with a soln. obtd. by dissolving an alcohol-soluble perfum in an alcoholic solution of a vinyl acetate resin and evaporating the alcohol. As the object, a 40-60-mesh sawdust of a Japanese cypress, a thick printed art paper, a roll- shaped thick non-woven fabric, a plaster, an unglazed pottery, a zeolite particle, etc., can be cited. The perfuming agent if different from a perfume alone or a perfuming compsn. wherein a liq. fixer is incorporated and exhibits no adhesive and dyeing properties to a substance in contact with it and exhibits furthermore such a feature that it emits a sweet smell for a long time.
INTRODUCTION: Kidney transplantation is a definitive treatment for end-stage renal disease. It is associated with improved life expectancy and quality of life. One of the most common complications following kidney transplantation is graft rejection. To our knowledge, no previous study has identified rejection risk factors in kidney transplant recipients in Saudi Arabia. Therefore, this study aimed to determine the specific risk factors of graft rejection.
METHODS: A multicenter case-control study was conducted at four transplant centers in Saudi Arabia. All adult patients who underwent a renal transplant between January 1, 2015 and December 31, 2021 were screened for eligibility. Included patients were categorized into two groups (cases and control) based on the occurrence of biopsy-proven rejection within 2 years. The primary outcome was to determine the risk factors for rejection within the 2 years of transplant. Exact matching was utilized using a 1:4 ratio based on patients' age, gender, and transplant year.
RESULTS: Out of 1,320 screened renal transplant recipients, 816 patients were included. The overall prevalence of 2-year rejection was 13.9%. In bivariate analysis, deceased donor status, the presence of donor-specific antibody (DSA), intraoperative hypotension, Pseudomonas aeruginosa, Candida, and any infection within 2 years were linked with an increased risk of 2-year rejection. However, in the logistic regression analysis, the presence of DSA was identified as a significant risk for 2-year rejection (adjusted OR: 2.68; 95% CI: 1.10, 6.49, p = 0.03). Furthermore, blood infection, infected with Pseudomonas aeruginosa or BK virus within 2 years of transplant, were associated with higher odds of 2-year rejection (adjusted OR: 3.10; 95% CI: 1.48, 6.48, p = 0.003, adjusted OR: 3.23; 95% CI: 0.87, 11.97, p = 0.08 and adjusted OR: 2.76; 95% CI: 0.89, 8.48, p = 0.07, respectively).
CONCLUSION: Our findings emphasize the need for appropriate prevention and management of infections following kidney transplantation to avoid more serious problems, such as rejection, which could significantly raise the likelihood of allograft failure and probably death. Further studies with larger sample sizes are needed to investigate the impact of serum chloride levels prior to transplant and intraoperative hypotension on the risk of graft rejection and failure.
Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.